MBB Public Markets I LLC Purchases New Position in Charles River Laboratories International, Inc. $CRL

Key Points

• MBB Public Markets I LLC acquired 1,887 shares of Charles River Laboratories International, Inc., valued at approximately $284,000, during the first quarter.
• Investment analysts have issued varied ratings for CRL, with Jefferies Financial Group upgrading the stock from "hold" to "buy" and raising the target price to $195.00.
• Charles River Laboratories reported $3.12 earnings per share for the last quarter, exceeding analysts' expectations of $2.50, with revenue reaching $1.03 billion.

MBB Public Markets I LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,887 shares of the medical research company's stock, valued at approximately $284,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Brooklyn Investment Group lifted its stake in Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after purchasing an additional 86 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Charles River Laboratories International by 2.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock worth $589,000 after buying an additional 102 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Charles River Laboratories International by 2.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock worth $763,000 after buying an additional 105 shares during the period. Veracity Capital LLC increased its position in Charles River Laboratories International by 3.4% during the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock worth $496,000 after buying an additional 107 shares during the period. Finally, Cambridge Investment Research Advisors Inc. increased its position in Charles River Laboratories International by 6.8% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,926 shares of the medical research company's stock worth $290,000 after buying an additional 123 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on CRL. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their price objective for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Evercore ISI raised their target price on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. JPMorgan Chase & Co. boosted their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Finally, Wall Street Zen raised shares of Charles River Laboratories International from a "buy" rating to a "strong-buy" rating in a report on Saturday. Six analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average target price of $177.07.

Charles River Laboratories International Trading Up 2.3%

CRL traded up $3.51 on Wednesday, reaching $155.11. 655,425 shares of the company's stock were exchanged, compared to its average volume of 1,214,354. The company's 50 day moving average is $160.62 and its 200-day moving average is $148.54. The company has a market cap of $7.63 billion, a price-to-earnings ratio of -116.66, a PEG ratio of 4.87 and a beta of 1.47. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $230.02. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. The firm had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.80 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).